Pharmacokinetic profile of iobitridol.
Iobitridol (Xenetix) is a new triiodinated monomer, nonionic, low-osmolality contrast agent. Animal pharmacokinetic studies (rats, rabbits, dogs) and in vitro studies show that it is a marker of extracellular fluid, i.e. it is distributed in the interstitial space, it does not penetrate into cells, it does not cross the healthy blood-brain barrier (BBB), it does not bind to proteins, and it is eliminated by glomerular filtration without secretion or reabsorption. These characteristics determine its use as an urography and angiography contrast agent as well as the precautions necessary to be taken, which are classical for contrast agents of this classification, related to administration in pathophysiologic populations (patients with renal failure, pregnant women or nursing mothers, neonates, etc. )
Dencausse
A
A
Research Center, Laboratoire Guerbert, Roissy Charles de Gaulle, France.
Violas
X
X
Feldman
H
H
Havard
P
P
Chambon
C
C
D000818:Animals; D002851:Chromatography, High Pressure Liquid; D003287:Contrast Media / Q000378:metabolism / Q000493:pharmacokinetics*; D004285:Dogs; D005260:Female; D000882:Haplorhini; D006801:Humans; D007472:Iohexol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000493:pharmacokinetics; D011247:Pregnancy; D011817:Rabbits; D051381:Rats; D017207:Rats, Sprague-Dawley; D013056:Spectrophotometry, Ultraviolet
D003287:Contrast Media; C093233:iobitridol; D007472:Iohexol